Tove Øyjord

  • Technician
  • +47 22 78 18 74
 

Publications 2023

Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 7339
DOI 10.1038/s41598-023-34087-x, PubMed 37147361

Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 9186
DOI 10.1038/s41598-023-36328-5, PubMed 37280349

Publications 2019

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Publications 2016

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843

Publications 2015

Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L (2015)
Metabolic reprogramming supports the invasive phenotype in malignant melanoma
Cancer Lett, 366 (1), 71-83
DOI 10.1016/j.canlet.2015.06.006, PubMed 26095603

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943

Publications 2010

Andersen K, Mori H, Fata J, Bascom J, Oyjord T, Mælandsmo GM, Bissell M (2010)
The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis
Dev Biol, 352 (2), 181-90
DOI 10.1016/j.ydbio.2010.12.033, PubMed 21195708

Publications 2006

Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
Tumour Biol, 28 (1), 27-35
DOI 10.1159/000097700, PubMed 17143014

Publications 1997

de Graaf H, Maelandsmo GM, Ruud P, Forus A, Oyjord T, Fodstad O, Hovig E (1997)
Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2
Int J Cancer, 72 (1), 191-6
DOI 10.1002/(sici)1097-0215(19970703)72:1<191::aid-ijc27>3.0.co;2-l, PubMed 9212242

Publications 1996

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425

Publications 1994

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277

Publications 1993

ANDREASSEN A, BORRESEN AL, OYJORD T, SOLHEIM OP, FLORENES VA, BRULAND O, MYKLEBOST O, HOIE J, FODSTAD O (1993)
CHROMOSOME-17P ABERRATIONS AND P53 EXPRESSION IN HUMAN SARCOMAS
FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 419-422

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179